TY - JOUR T1 - Effectiveness and durability of the mRNA vaccine-induced SARS-CoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy JF - medRxiv DO - 10.1101/2022.02.17.22271122 SP - 2022.02.17.22271122 AU - Michal Podrazil AU - Pavla Taborska AU - Dmitry Stakheev AU - Michal Rataj AU - Jan Lastovicka AU - Alena Vlachova AU - Petr Pohunek AU - Jirina Bartunkova AU - Daniel Smrz Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/17/2022.02.17.22271122.abstract N2 - The COVID-19 vaccines effectively elicit humoral and cellular immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a healthy population. This immunity decreases several months after the vaccination. However, the efficacy of the vaccine-induced immunity and its durability in patients with severe asthma on biological therapy is unknown. In this study, we evaluated the effectiveness and durability of the mRNA vaccine-induced SARS-CoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy. The study included 37 patients with severe asthma treated with anti-IgE (omalizumab, n=18), anti-IL5 (mepolizumab, n=14; reslizumab, n=4), or anti-IL5R (benralizumab, n=1) biological therapy. All patients were vaccinated with two doses of BNT162b2 mRNA vaccine (Comirnaty) at a 6-week period between the doses. We found that the COVID-19 vaccination elicited SARS-CoV-2-specific humoral and cellular immunity, which significantly declined 6 months after the second dose of the vaccine. The type of biological treatment did not affect the vaccine-elicited immunity. However, the patients’ age negatively impacted the vaccine-induced humoral response. On the other hand, no such age-related impact was observed on the vaccine-elicited cellular immunity. Our findings showed that biological therapy of patients with severe asthma does not compromise the effectiveness and durability of the COVID-19 vaccine-induced immunity.Competing Interest StatementJ.B. is a part-time employee and a minority shareholder of Sotio, a.s. P.P. is a member of the advisory board of the GSK and received a consultancy fee from AstraZeneca, Novartis, Chiesi and speakers fee from GSK and Novartis. M.P., P.T., D.S., M.R, J.L., A.V., and Da.S. declare no conflicts of interest.Funding StatementResearch in the authors' laboratories was supported by the institutional IPE2 funding of the Charles University, Second Faculty of Medicine in Prague.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee/IRB of the Motol University Hospital in Prague gave ethical approval for this work. The protocol approval number is EK-346/21.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -